RT Journal Article
SR Electronic
T1 Identifying intergenerational risk factors for ADHD symptoms using polygenic scores in the Norwegian Mother, Father and Child Cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.16.21251737
DO 10.1101/2021.02.16.21251737
A1 Pingault, Jean-Baptiste
A1 Barkhuizen, Wikus
A1 Wang, Biyao
A1 Hannigan, Laurie J.
A1 Eilertsen, Espen Moen
A1 Andreassen, Ole A.
A1 Ask, Helga
A1 Tesli, Martin
A1 Askeland, Ragna Bugge
A1 Smith, George Davey
A1 Davies, Neil
A1 Reichborn-Kjennerud, Ted
A1 Ystrom, Eivind
A1 Havdahl, Alexandra
YR 2021
UL http://medrxiv.org/content/early/2021/02/20/2021.02.16.21251737.abstract
AB Importance Knowledge of the mechanisms underlying the intergenerational transmission of risk for attention-deficit/hyperactivity disorder (ADHD) symptoms can inform psychosocial interventions.Objective To investigate whether parental genetic risk factors associate with their children’s ADHD symptoms due to genetic transmission of risk or due to parental genetic liability that influences offspring ADHD via parenting environments (genetic nurture).Design and participants This study is based on the Norwegian Mother, Father and Child Cohort Study and uses data from the Medical Birth Registry of Norway. This prospective cohort study consisted of 5,405 mother-father-offspring trios recruited between 1999 – 2008.Exposures We calculated polygenic scores for parental traits previously associated with ADHD, including psychopathology, substance use, neuroticism, educational attainment and intellectual ability.Main outcomes and measures Mothers reported on their 8-year-old children’s ADHD symptoms using the Parent/Teacher Rating Scale for Disruptive Behavior Disorders.Results Maternal polygenic scores for ADHD, autism spectrum disorder (ASD), neuroticism and smoking predicted child ADHD symptoms in bivariate analyses. After jointly modelling maternal, paternal and child polygenic scores, ADHD symptoms were predicted by children’s polygenic scores for ADHD (β = 0.10; 95% CI 0.07 to 0.14), smoking (β = 0.07; 95% CI 0.03 to 0.10) and educational attainment (β = −0.09; 95% CI −0.13 to −0.05), indicating direct genetic transmission of risk. Mothers’ polygenic scores for ASD (β = 0.05; 95% CI 0.02 to 0.08) and neuroticism (β = 0.05; 95% CI 0.01 to 0.08) predicted children’s ADHD symptoms conditional on fathers’ and children’s scores, implicating genetic nurture, or effects due to population stratification or assortative mating.Conclusions These results suggest that associations between some parental traits and offspring ADHD symptoms likely reflect a nuanced mix of direct genetic transmission (ADHD, smoking and educational attainment) and genetic nurture (ASD and neuroticism). If confirmed, these findings support previous evidence that maternal ASD or neuroticism may be possible targets for intervention to help break the chain of the intergenerational transmission of ADHD risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Research Council of Norway supported EME (#262177), EY (#262177 and #288083), TRK, HA and RBA (#274611) and AH (#288083). AH and LJH was supported by the South-Eastern Norway Regional Health Authority (2020022 and 2018058, respectively). JBP is supported by the Medical Research Foundation 2018 Emerging Leaders 1st Prize in Adolescent Mental Health (MRF-160-0002-ELP-PINGA). GDS is supported by the Medical Research Council (MRC) and the University of Bristol [MC_UU_00011/1]. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 863981). The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_00011/1]. NMD is supported by a Norwegian Research Council Grant number 295989.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Regional Committees for Medical and Health Research Ethics (REK; 2016/1702).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to MoBa data requires approval from The Norwegian Institute of Public Health (NIPH). https://www.fhi.no/en/more/access-to-data/applying-for-access-to-data/